Molecular Partners Ag (MOLN) Share-based Compensation (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Share-based Compensation of $1195.3 for Q1 2026, down 5.9% year-over-year from $1270.2 in Q1 2025, and down 99.98% quarter-over-quarter from $5.5 million in Q4 2025.
Molecular Partners Ag (MOLN) Share-based Compensation (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Share-based Compensation for 7 consecutive years, with $1195.3 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 5.9% year-over-year to $1195.3; the TTM figure through Mar 2026 stood at $4.1 million (up 11.07% YoY), while the FY2025 annual figure was $5.5 million, up 17.99% from the prior year.
- Share-based Compensation eased to $1195.3 in Q1 2026 per MOLN's latest filing, from $5.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.9 million in Q4 2023 and bottomed at -$3.5 million in Q3 2023.
- Historically, Share-based Compensation has averaged $909222.3 across 5 years, with a median of $1888.8 in 2023.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 67.26% — and 2024, when it slumped 48.2%.
- Molecular Partners Ag's Share-based Compensation stood at $5.3 million in 2022, then grew by 11.15% to $5.9 million in 2023, then dropped by 20.17% to $4.7 million in 2024, then rose by 17.98% to $5.5 million in 2025, then slumped by 99.98% to $1195.3 in 2026.
- Business Quant data shows MOLN's Share-based Compensation at $1195.3 in Q1 2026, $5.5 million in Q4 2025, and -$3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 1,195.28 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,195.28 |
| Mar 31, 2026 | 1,195.28 |
| Dec 31, 2025 | 5.52 Mn |
| Dec 31, 2025 | 5.52 Mn |
| Sep 30, 2025 | -2.96 Mn |
| Sep 30, 2025 | -2.96 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 1,270.19 |
| Mar 31, 2025 | 1,270.19 |
| Dec 31, 2024 | 4.68 Mn |
| Dec 31, 2024 | 4.68 Mn |
| Sep 30, 2024 | -2.29 Mn |
| Sep 30, 2024 | -2.29 Mn |
| Jun 30, 2024 | 1.25 Mn |
| Jun 30, 2024 | 1.25 Mn |
| Mar 31, 2024 | 978.41 |
| Mar 31, 2024 | 978.41 |
| Dec 31, 2023 | 5.87 Mn |
| Dec 31, 2023 | 5.87 Mn |